Abu Dhabi – Mubasher: Gulf Pharmaceutical Industries (Julphar), listed on the Abu Dhabi Securities Exchange (ADX), has turned to losses during the first quarter of 2019.
The company had incurred AED 91.6 million in losses in Q1-19, against profits of AED 18.4 million in Q1-18, according to a statement to the ADX.
Loss per share stood at AED 7.7 during the three-month period ended 31 March 2019, compared to earnings per share of AED 1.7 in the year-ago period.
Operating loss reached AED 84.8 million in the first three months of the year, versus an operating profit of AED 22 million in Q1-18.
Total assets amounted to AED 2.68 billion at the end of March 2019, down from AED 2.86 billion as at 31 December 2018.
In 2018, Julphar turned to loss, suffering a net loss of AED 153 million, against a profit of AED 90.3 million in 2017.
